PODD
$282.80
Insulet
($5.49)
(1.90%)
PODD
Earnings Whisper ®
N/A
1st Quarter March 2025
Consensus:  $0.79
Revenue:  N/A
Thursday
May 22
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when PODD reports earnings?
Beat
Meet
Miss

Where is PODD's stock price going from here?
Up
Flat
Down
Stock chart of PODD
Analysts
Summary of analysts' recommendations for PODD
Score
Grade
Pivots
Resistance
$299.81
$293.24
$288.02

$281.44

Support
$276.22
$269.65
$264.43
Tweet
Growth
Description
Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas.
Peers
Boston ScientificStrykerAbbottWatersBecton, DickinsonResMed3MBaxter InternationalTeleflexIntegra LifeSciences Holdings